New RNA Tech Aims to Unravel Autoimmunity's Deepest Secrets

MIAMI and MONTEVIDEO, Uruguay – April 07, 2026 – In a significant step toward revolutionizing the treatment of autoimmune diseases, US-based Resolve Therapeutics and Uruguay's prestigious Institut Pasteur de Montevideo have announced a landmark collaboration. The partnership aims to decode the very first molecular signals that trigger the body's immune system to attack itself in diseases like lupus and Sjögren's syndrome, harnessing a novel technology capable of reading genetic messages previously thought to be lost forever.

This international alliance brings together a clinical-stage biopharmaceutical company with a leading academic research institution to tackle one of modern medicine's most persistent challenges: identifying the root cause of autoimmune inflammation. By focusing on the upstream triggers, they hope to pave the way for a new generation of targeted, non-immunosuppressive therapies that could transform millions of lives.

The Elusive Triggers of Autoimmunity

Autoimmune diseases, a category of over 80 chronic conditions, occur when the body's natural defense system mistakenly attacks its own healthy tissues. For millions suffering from diseases such as lupus and Sjögren's, life is a constant battle against symptoms like debilitating fatigue, chronic pain, and organ damage. Current treatments often rely on broad immunosuppressants, which, while helpful, turn down the entire immune system, leaving patients vulnerable to infections and other serious side effects.

The scientific community has long suspected that the initial spark for this self-destructive inflammatory cascade lies in tiny molecules circulating in the blood. Recent research points to cell-free RNA (cfRNA)—specifically, damaged self-RNA and fragments from ancient, dormant viruses embedded in our genome—as the most proximal triggers. When these RNA molecules are released from dying cells, the immune system can misidentify them as foreign invaders, launching a relentless and self-perpetuating attack. The critical challenge, however, has been studying these molecules. By their very nature, they are fragile, degraded, and present in vanishingly small quantities, making them effectively invisible to conventional genetic sequencing technologies.

A Technological Breakthrough: REJOIN-seq

The collaboration's key is a pioneering technology called REJOIN-seq, developed at the Institut Pasteur de Montevideo. This innovative method directly addresses the problem of RNA fragility. Where conventional sequencing fails, REJOIN-seq acts like a molecular restoration expert, painstakingly repairing and reassembling partially degraded cfRNA fragments. This allows scientists, for the first time, to sequence and analyze a wealth of previously inaccessible information about the earliest stages of autoimmune disease.

This technology is the brainchild of Dr. Juan Tosar, chief of functional genomics at the Pasteur, whose work in the field is highly regarded. Resolve Therapeutics' CEO, Dr. James Posada, praised his new collaborator, noting, "Pasteur's Dr. Tosar has published some of the most careful, exacting science in the field of cfRNA, we are thrilled to work with his team."

The potential of this technology is immense. By identifying the specific cfRNA molecules that drive inflammation in lupus and Sjögren's patients, researchers can develop therapies designed to neutralize these triggers specifically, without shutting down the entire immune system. "We are confident that combining our next generation REJOIN-seq technology with Resolve's clinical programs will unlock information regarding the upstream events that trigger the inflammatory cascade in autoimmunity," commented Dr. Tosar.

A Strategic Alliance for Patient Impact

This partnership represents a powerful synergy between academic innovation and clinical application. The Institut Pasteur de Montevideo, a member of the globally respected Pasteur Network, brings world-class expertise in basic science and RNA biology. Resolve Therapeutics, meanwhile, contributes its deep experience in drug development and its existing pipeline of non-immunosuppressive therapies.

Resolve is already advancing RSLV-132, a mid-stage clinical asset that has shown promise in improving disease activity in both lupus and Sjögren's. The company's focus is on developing drugs that target harmful cfRNA and another inflammatory trigger known as neutrophil extracellular traps (NETs). Integrating REJOIN-seq into these clinical programs will create a powerful feedback loop: patient samples from trials can be analyzed to identify new cfRNA targets, and the efficacy of drugs like RSLV-132 in neutralizing these targets can be precisely measured.

"Embedding Pasteur's next generation RNA-seq technology within Resolve's clinical programs provides a unique opportunity to significantly advance our understanding of cfRNA in autoimmune diseases," Dr. Posada stated. This approach moves beyond simply managing symptoms and aims to dismantle the disease mechanism at its source, promising a future of more effective and safer treatments for patients.

Beyond Lupus: The Broader Implications

The impact of this collaboration could extend far beyond its initial focus. The ability to identify and analyze degraded cfRNA has profound implications for a wide range of diseases where inflammation plays a key role. Resolve's own pipeline hints at this broader potential, with a second compound, RSLV-145, being developed for acute ischemic stroke, a condition where NETs and nucleic acids are known to worsen outcomes.

While the field of liquid biopsy has seen an explosion of interest in using cfRNA for cancer diagnostics, the therapeutic targeting of cfRNA in autoimmunity remains a relatively new frontier. This collaboration positions Resolve and the Institut Pasteur at the vanguard of this emerging field. The unique power of REJOIN-seq could provide a significant competitive advantage, allowing them to discover and validate novel drug targets that are simply invisible to competitors using standard methods.

Ultimately, this global partnership between a US biotech and a Uruguayan research center exemplifies the modern, collaborative nature of scientific discovery. By bridging borders and combining specialized expertise, they are poised to make significant inroads against a complex and debilitating class of diseases. For the millions living with the daily burden of autoimmunity, this union of cutting-edge science and clinical ambition represents a new and powerful beacon of hope on the medical horizon.